Scandion Oncology announced that Bo Rode Hansen from October 1 is appointed CEO of the company. This planned evolution in the leadership of Scandion Oncology is executed to allow co-founder, Nils Brünner to focus his time, and world-renowned oncology expertise on the continued clinical development of pipeline and to further strengthen technology platform DEN50-R. The change provides the right balance and strength in the executive management team to bring Scandion Oncology to the next level of its corporate, scientific and pipeline development. The new President & CEO, Dr. Bo Rode Hansen is a seasoned top executive and life science entrepreneur with decades of leadership experience from both Scandinavian and international pharma and biotech (Santaris Pharma (DK), Roche (CH) and Genevant Sciences (US)).